213 related articles for article (PubMed ID: 37063886)
1. Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients.
Chen H; Yang W; Ji Z
Front Immunol; 2023; 14():1171420. PubMed ID: 37063886
[TBL] [Abstract][Full Text] [Related]
2. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
Front Immunol; 2022; 13():964393. PubMed ID: 36211344
[TBL] [Abstract][Full Text] [Related]
3. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
4. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
5. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analyses of a tumor-infiltrating lymphocytes-related gene signature regarding the prognosis and immunologic features for immunotherapy in bladder cancer on the basis of WGCNA.
He Z; Gu J; Luan T; Li H; Li C; Chen Z; Luo E; Wang J; Huang Y; Ding M
Front Immunol; 2022; 13():973974. PubMed ID: 36211333
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
8. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
[TBL] [Abstract][Full Text] [Related]
9. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer.
Zhou M; Zhang Z; Bao S; Hou P; Yan C; Su J; Sun J
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32382761
[TBL] [Abstract][Full Text] [Related]
10. Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy.
Yao Y; Wang J; Yang F; Gao W
Front Immunol; 2022; 13():924498. PubMed ID: 35844536
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
[TBL] [Abstract][Full Text] [Related]
12. Integrated Analysis Revealed an Inflammatory Cancer-Associated Fibroblast-Based Subtypes with Promising Implications in Predicting the Prognosis and Immunotherapeutic Response of Bladder Cancer Patients.
Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555612
[TBL] [Abstract][Full Text] [Related]
13. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
Xu Y; Sun X; Liu G; Li H; Yu M; Zhu Y
Front Immunol; 2023; 14():1301157. PubMed ID: 38299148
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients.
Ma L; Chen H; Yang W; Ji Z
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902193
[TBL] [Abstract][Full Text] [Related]
15. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
Front Immunol; 2022; 13():898493. PubMed ID: 35812369
[TBL] [Abstract][Full Text] [Related]
16. Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer.
Xie T; Peng S; Liu S; Zheng M; Diao W; Ding M; Fu Y; Guo H; Zhao W; Zhuang J
Mol Cancer; 2024 Feb; 23(1):30. PubMed ID: 38341586
[TBL] [Abstract][Full Text] [Related]
17. The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma.
Wan Z; Wang Y; Li C; Zheng D
Open Life Sci; 2023; 18(1):20220682. PubMed ID: 37588995
[TBL] [Abstract][Full Text] [Related]
18. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
Front Immunol; 2021; 12():791924. PubMed ID: 34975891
[TBL] [Abstract][Full Text] [Related]
19. Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
Zhou R; Zhou J; Muhuitijiang B; Zeng X; Tan W
Aging (Albany NY); 2023 Jun; 15(12):5355-5380. PubMed ID: 37379131
[TBL] [Abstract][Full Text] [Related]
20. Expression of EPB41L2 in Cancer-Associated Fibroblasts: Prognostic Implications for Bladder Cancer and Response to Immunotherapy.
Wang T; Ding G; Wang X; Cui Y; Ma X; Ma J; Wu J
Arch Med Res; 2024 Jan; 55(1):102927. PubMed ID: 38154234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
